PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Clinical evidence
A phytocompound (K-712) containing 10% oleoresin of P. colorata (30% polygodial) was tested for clinical efficacy compared to itraconazole; the treatment was reported as well tolerated with only 3 patients reporting slight dyspepsia [PMID:24152852].
A prospective randomized study evaluated a phytocompound (K-712) containing 10 mg of P. colorata oleoresin (30% polygodial) over a 12-month period [PMID:22217987].
Polygodial from P. colorata is identified as an anti-Candida agent [PMID:7089094].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 34946177 (2021) — Fungal Communities in the Native New Zealand Medicinal Plant Pseudowintera colorata (Horopito) Are Determined by Plant Organ Type and Host Maturity with Key Members Promoting Plant Growth. · Microorganisms
- 2.PMID: 32012657 (2020) — Community Structure, Diversity and Potential of Endophytic Bacteria in the Primitive New Zealand Medicinal Plant Pseudowintera colorata. · Plants (Basel, Switzerland)
- 3.PMID: 29435598 (2018) — Community Structure of Endophytic Actinobacteria in a New Zealand Native Medicinal Plant Pseudowintera colorata (Horopito) and Their Influence on Plant Growth. · Microbial ecology
- 4.PMID: 7089094 (1982) — Antibiotic substances from New Zealand plants. II. Polygodial, an anti-Candida agent from Pseudowintera colorata. · Planta medica
- 5.PMID: 20176388